U
PRPH

UBS’s ProPhase Labs PRPH Stock Holding History

UBS’s Portfolio PRPH Stock Details PRPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$37K Buy
2,666
+2,616
+5,232% +$40.7K ﹤0.01% 7195
2014
Q2 		$1K Sell
50
-194
-80% -$3.59K ﹤0.01% 10234
2014
Q1 		$5K Sell
244
-159
-39% -$3.02K ﹤0.01% 9542
2013
Q4 		$7K Buy
403
+15
+4% +$270 ﹤0.01% 9329
2013
Q3 		$8K Buy
388
+41
+12% +$687 ﹤0.01% 9023
2013
Q2 		$5K Buy
+347
New +$5.41K ﹤0.01% 9256

Other funds holding PRPH

VIP
Vantage Investment Partners Kansas City, Missouri $1.45B AUM 18.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

UBS's PRPH Position: Q3 2014 in Review

UBS increased its ProPhase Labs (PRPH) stake by 5,232% in Q3 2014, buying an estimated $40.7K and bringing the position to 2,666 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #7195.

UBS first reported a position in PRPH in Q2 2013 and has held it in 6 quarters since. 18 funds tracked by Wall St. Rank hold PRPH as of Q3 2014.

  • UBS held 2,666 shares of ProPhase Labs worth $37K as of Q3 2014.
  • UBS bought 2,616 ProPhase Labs shares in Q3 2014, an estimated $40.7K.
  • ProPhase Labs made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7195 holding.
  • UBS first reported a position in ProPhase Labs in Q2 2013 and has held it in 6 quarters since.
  • 18 funds tracked by Wall St. Rank held ProPhase Labs as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.